Inflammatory Bowel Disease (IBD) Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (TNF Inhibitors, Corticosteroids, Amino Salicylates, Immunomodulators, Others), By Disease Indication (Ulcerative Colitis, Crohn’s Disease), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region and Competition, 2020-2030F

Market Overview

The Global Inflammatory Bowel Disease (IBD) Drugs Market, valued at USD 22.91 Billion in 2024, is projected to experience a CAGR of 5.40% to reach USD 31.41 Billion by 2030. The Global Inflammatory Bowel Disease (IBD) Drugs Market encompasses pharmaceutical agents designed to manage chronic inflammatory conditions of the gastrointestinal tract, primarily Crohn's disease and ulcerative colitis, utilizing various drug classes including biologics, immunomodulators, and small molecules. Market growth is principally driven by the rising global prevalence of IBD, significant advancements in targeted therapeutic development, and increasing healthcare expenditure aimed at improving patient access to advanced treatments.

According to the European Federation of Crohn's and Ulcerative Colitis Associations, in 2022, approximately 10 million individuals worldwide were living with IBD, underscoring the substantial patient population. A notable challenge impeding market expansion is the high cost associated with innovative biologic and specialized therapies, which can limit affordability and accessibility for a considerable segment of the patient demographic.

Key Market Drivers

Two principal factors significantly influencing the global inflammatory bowel disease drugs market are the increasing global prevalence of inflammatory bowel disease and the continuous advancements in biologic and novel drug therapies. The rising incidence and growing patient population globally naturally expand the demand for effective treatment options. For instance, according to an Elsevier Ltd. report, in August 2023, the prevalence of ulcerative colitis alone was estimated to be around 5 million cases worldwide, underscoring a substantial and persistent patient demographic requiring ongoing pharmacological management. This expanding patient base directly translates into a greater need for therapeutic interventions, thereby fueling market expansion for IBD drugs.

Further driving market growth is the consistent innovation in therapeutic development, particularly with biologics and small molecules, offering improved outcomes for patients with moderate to severe IBD. These advancements lead to the introduction of more targeted and effective treatments, increasing therapeutic options and uptake. According to the European Medicines Agency, in 2024, 28 new biosimilar products were recommended for marketing authorization, covering various diseases including ulcerative colitis and Crohn's disease, reflecting significant progress in making advanced therapies more accessible. The broader IBD drug market is further characterized by organized research efforts, where, according to Oxford Academic, in May 2024, "Challenges in IBD Research 2024: Pragmatic Clinical Research", pragmatic clinical research constitutes one of five key focus areas for advancing patient-centric solutions. This sustained research and development activity ensures a robust pipeline of new therapies, reinforcing market dynamism.

Download Free Sample Report

Key Market Challenges

The challenging factor is the high cost associated with innovative biologic and specialized therapies, which limits affordability and accessibility for a significant portion of the patient demographic.

This high cost directly impedes the growth of the Global Inflammatory Bowel Disease Drugs Market by restricting patient access to crucial treatments. Even with the availability of effective advanced therapies, their substantial price often creates financial barriers for both individual patients and healthcare systems. According to a survey released by the Crohn's & Colitis Foundation in October 2024, among patients prescribed medication for their IBD in the past year, 63% faced financial barriers to obtaining medications, resulting in them not taking their IBD medications as prescribed. This issue directly translates into lower adoption rates and reduced market penetration for these high-value pharmaceutical products globally. Consequently, the market potential remains constrained as a considerable number of patients are unable to initiate or consistently adhere to optimal treatment regimens due to economic considerations.

Key Market Trends

The global inflammatory bowel disease (IBD) drugs market is significantly influenced by the accelerating shift towards personalized medicine approaches. This trend focuses on tailoring therapeutic interventions to individual patient profiles, moving beyond a one-size-fits-all treatment paradigm by integrating genetic, molecular, and clinical data to predict treatment response and optimize outcomes. The Crohn's & Colitis Foundation, an industrial association, underscored this strategic importance by identifying precision medicine as one of five key focus areas in its "Challenges in IBD Research 2024" report. This targeted approach aims to reduce trial-and-error in treatment selection, improve drug efficacy, and enhance patient adherence, thereby driving demand for advanced diagnostics and therapies. For instance, nference announced a research alliance with Takeda in July 2024, utilizing artificial intelligence to optimize patient care in IBD by analyzing de-identified electronic health records to identify patients who could benefit from advanced medical interventions, which aims to personalize treatment options.

Another pivotal trend shaping the IBD drugs market is the increasing integration of digital health and artificial intelligence (AI) in patient management. These technologies enhance patient monitoring, improve diagnostic accuracy, and facilitate more efficient disease management by providing real-time data and actionable insights to healthcare providers and patients alike. Reflecting its strategic significance, the Crohn's & Colitis Foundation, in its "Challenges in IBD Research 2024," highlighted novel technologies, which include digital health and AI, as another one of its five primary research focus areas. This integration leads to improved patient engagement, better adherence to treatment regimens, and a reduction in healthcare resource utilization, fostering a more proactive and preventative care model. Takeda, for example, partnered with Iterative Health, as reported in January 2025, to leverage AI and machine learning to improve endoscopic assessments in IBD research, aiming to advance clinical care and trial design by providing insights into disease severity and guiding treatment choices.

Segmental Insights

The TNF Inhibitors segment is experiencing rapid growth in the Global Inflammatory Bowel Disease (IBD) Drugs Market, primarily driven by their established efficacy and safety in inducing and maintaining remission in patients with moderate to severe Crohn's disease and ulcerative colitis. These biologics, including infliximab and adalimumab, effectively reduce inflammation, leading to improved symptom control and enhanced patient quality of life. Furthermore, significant investment in the development of these drugs by key market players and continuous product approvals, alongside the introduction of biosimilars, contribute to their increasing adoption and market expansion. This sustained growth highlights the integral role TNF inhibitors play in the current IBD treatment landscape. The TNF Inhibitors segment is experiencing rapid growth in the Global Inflammatory Bowel Disease (IBD) Drugs Market, primarily driven by their established efficacy and safety in inducing and maintaining remission in patients with moderate to severe Crohn's disease and ulcerative colitis. These biologics, including infliximab and adalimumab, effectively reduce inflammation, leading to improved symptom control and enhanced patient quality of life. Furthermore, significant investment in the development of these drugs by key market players and continuous product approvals, alongside the introduction of biosimilars, contribute to their increasing adoption and market expansion. This sustained growth highlights the integral role TNF inhibitors play in the current IBD treatment landscape.

Regional Insights

North America emerges as the leading region in the global Inflammatory Bowel Disease (IBD) drugs market, driven by several key factors. The region, notably the United States and Canada, exhibits a significant prevalence of Crohn's disease and ulcerative colitis, creating a substantial demand for effective therapies. This demand is met by a highly developed healthcare infrastructure that facilitates early diagnosis and comprehensive patient management. Furthermore, the widespread adoption of advanced biologic and targeted therapies, coupled with favorable reimbursement policies and robust insurance coverage, ensures broad patient access to costly but efficacious treatments. The strong presence of major pharmaceutical companies, alongside continuous innovation and strategic regulatory approvals by institutions like the U. S. Food and Drug Administration, collectively underpins North America's market dominance.

Recent Developments

• In February 2025, Sanofi and Teva Pharmaceuticals presented new detailed results from the RELIEVE UCCD Phase 2b study of duvakitug. Duvakitug, a human monoclonal antibody targeting TL1A, showed promising data in patients with moderate-to-severe ulcerative colitis and Crohn's disease. This collaboration involves both companies equally sharing global development costs, and net profits or losses in major markets. Sanofi is slated to lead the subsequent Phase 3 clinical development program for duvakitug, aiming to transform treatment for patients within the inflammatory bowel disease drugs market.

• In January 2025, Eli Lilly's Omvoh (mirikizumab) received U.S. Food and Drug Administration (FDA) approval for treating adults with moderately to severely active Crohn's disease. This marks the second indication for Omvoh in inflammatory bowel disease, following its prior approval for ulcerative colitis. The approval was based on positive outcomes from the Phase 3 VIVID-1 study, which demonstrated significant clinical remission and intestinal healing. This expanded approval strengthens Omvoh's position as an important interleukin-23p19 antagonist in the global IBD drugs market, offering patients a new therapeutic option.

• In June 2024, AbbVie acquired Celsius Therapeutics for $250 million in cash, further expanding its inflammatory bowel disease (IBD) drug pipeline. Celsius Therapeutics, a clinical-stage startup, brings a distinct approach to treating inflammation with its lead program, CEL383. This antibody is designed to block TREM1, a protein known to amplify inflammation, and was undergoing a Phase 1 clinical trial for IBD. This strategic acquisition underscores AbbVie's continued efforts to diversify its portfolio within the gastrointestinal therapeutic area of the global IBD drugs market.

• In February 2024, Pfizer received marketing authorization from the European Commission for Velsipity (etrasimod) in the European Union. This approval addresses patients aged 16 and older with moderately to severely active ulcerative colitis who have not responded adequately, lost response, or were intolerant to conventional or biological therapies. Velsipity, an oral, once-daily sphingosine 1-phosphate (S1P) receptor modulator, provides a new advanced treatment option for individuals living with this inflammatory bowel disease. This regulatory milestone follows previous approvals in the U.S. and Canada, expanding access to this therapy across the global IBD drugs market.

Key Market Players

• Takeda Pharmaceutical Company Limited
• AbbVie Inc.
• Pfizer Inc.
• UCB S.A.
• Johnson & Johnson
• Novartis AG
• Bristol Myers Squibb Co.
• Merck & Co., Inc.
• Celltrion, Inc.

Report Scope:

In this report, the Global Inflammatory Bowel Disease (IBD) Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Inflammatory Bowel Disease (IBD) Drugs Market, By Drug Class:

o   TNF Inhibitors

o   Corticosteroids

o   Amino salicylates

o   Immunomodulators

o   Others

• Inflammatory Bowel Disease (IBD) Drugs Market, By Disease Indication:

o   Ulcerative Colitis

o   Crohn’s Disease

• Inflammatory Bowel Disease (IBD) Drugs Market, By Route of Administration:

o   Oral

o   Injectable

• Inflammatory Bowel Disease (IBD) Drugs Market, By Distribution Channel:

o   Hospital Pharmacy

o   Retail Pharmacy

o   Online Pharmacy

• Inflammatory Bowel Disease (IBD) Drugs Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Inflammatory Bowel Disease (IBD) Drugs Market.

Available Customizations:

Global Inflammatory Bowel Disease (IBD) Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Inflammatory Bowel Disease (IBD) Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]